There was bipartisan support for the PASTEUR Act’s approach to addressing AMR and for NSCEB recommendations, both BIO priorities. A bipartisan Senate hearing sought […]
Senators seek solutions for AMR, maintaining US biotech leadership Read More »
Listening to people’s concerns about vaccines is key to helping them regain trust, according to experts promoting the need for life-saving immunizations. “We’ve all
BIO 2026: To restore trust in vaccines, listen to everyone’s concerns Read More »
“CAR-T cell therapies are remarkable drugs and are the gold standard for patients,” said Rachel Haurwitz, PhD, President & CEO of Caribou Biosciences. These
BIO 2026: Realizing the promise of CAR-T cell therapies Read More »
While the U.S. Food and Drug Administration (FDA) has faced significant change in recent years, industry leaders and agency officials alike say there are
BIO 2026: FDA leaders discuss restoring workforce, institutional knowledge Read More »
Industry leaders at BIO 2026 discussed the proposed PDUFA VIII next steps. After a year of discussion with the industry and 127 meetings with
BIO 2026: Industry PDUFA negotiators describe their agreement with FDA Read More »
Experts at the BIO International Convention examine the growth of the 340B drug pricing program, duplicate discounts, patient access, and calls for greater transparency.
BIO 2026: 340B faces growing calls for transparency, patient-focused reform Read More »
From sickle cell disease to multiple sclerosis and childhood leukemia, patients and advocates reflected on becoming pioneers in therapies that are changing medicine.
BIO 2026: ‘I am alive today because of biotech’ Read More »
What started as a conversation, in a bar, written on a napkin in 1976, between biochemist Dr. Herbert W. Boyer and investor Robert A.
After 50 years of biotech, can AI help answer the next impossible question? Read More »
Gary Sinise, Marcus Freeman, and BIO President & CEO John F. Crowley discussed leadership, resilience, and purpose at BIO 2026, drawing lessons from military
BIO 2026: Gary Sinise, Marcus Freeman on leadership, service, and resilience Read More »
The Reagan-Udall Foundation for the FDA just released a new report on strengthening early-stage drug development in the United States. The report reflects insights
New report details how U.S. can maintain biotech competitiveness Read More »
